Inovio wins case in dispute with VGXI, GeneOne Life Science (INO:NASDAQ)

INOVIO (INO) won a lawsuit against VGXI and GeneOne, securing $80.4M in damages and fees. The court ruled in INOVIO's favor on all claims, but defendants' financial condition may hinder collection. INOVIO plans to pursue recovery efforts.

INOVIO (INO) won an $80.4M judgment against VGXI and GeneOne, including $61.8M in damages and $18.7M in fees. The company cautioned that the defendants' financial condition may hinder collection.

INOVIO won an $80.4M court judgment against defendants for breaching a supply agreement, but their financial condition may hinder collection. INOVIO plans to pursue recovery. INOVIO is a biotech company focused on DNA medicines for cancer and infectious diseases. The company cautioned that collection is uncertain and may be reduced or reversed.

Inovio (INO) discussed its Q2 2026 earnings call, focusing on FDA progress for its BLA for INO-3110 for recurrent respiratory papillomatosis. The FDA completed late-cycle review and prelicensure inspections, and Inovio expects the Oct. 30 PDUFA date. The company reported $18.3M net proceeds from a late-July equity offering and expects cash into late Q1 2027.

Inovio Pharmaceuticals said the FDA completed all scheduled pre-licensure inspections, with one observation addressed. Management reiterated that INO-3107 meets accelerated approval criteria and expects label negotiations in Sept 2026 ahead of an Oct 30 PDUFA. Cash runway extends into late Q1 2027 after a July 2026 $18.3M equity offering; Q3 2026 net cash burn is $18M.

INOVIO (NASDAQ: INO) reported Q2 2026 results and said the FDA review of its BLA for INO-3107 in recurrent respiratory papillomatosis is progressing toward a PDUFA target date of Oct. 30, 2026. Cash and investments were $36.7M at June 30, 2026. Net loss was $6.0M. ApolloBio reported positive Phase 3 topline results for VGX-3100 in China.